Strengths and limitations
RECRUITMENT, BREAST CANCER
Strengths of our study include recruitment from multiple sites, high rate of data completion, and inclusion of both objective and patient‐reported cognitive outcomes. There are also notable limitations to acknowledge. Most significantly, the use of a historical control limited our ability to make direct comparisons to evaluate efficacy, and a follow‐up randomized trial is planned for this purpose. Regarding generalizability, participants who enrolled in our study may have had more concerns about their cognition entering treatment and/or were more optimistic about memantine's potential to benefit them, which may have led to bias, especially in patient‐reported symptoms. Participants also had high levels of education and were about 5 years younger than the average age of patients diagnosed with breast cancer.